Published on: December 01, 2017 at 10:00AM
Condition: Urothelial/Bladder Cancer, Nos
Interventions: Drug: Atezolizumab; Biological: PGV001; Drug: Poly ICLC; Drug: Normal saline
Sponsors: Matthew Galsky; Genentech, Inc.
Not yet recruiting
http://ift.tt/2zWr7Hc
No comments:
Post a Comment